Navigation Links
CerSci Therapeutics Awarded Phase II SBIR Grant from the National Institute on Drug Abuse of the National Institutes of Health
Date:8/1/2017

DALLAS, Aug. 1, 2017 /PRNewswire/ -- CerSci Therapeutics, a non-opioid drug development firm based in Dallas, Texas, has received notice from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) that it has been awarded a Direct-to-Phase II Small Business Innovation Research (SBIR) grant totaling over $650,000 in 2017 with an additional $1,000,000 to follow in 2018. These funds will support CerSci's Investigational New Drug application of their lead non-opioid drug candidate CT-044 to the Food and Drug Administration targeting submission in 3rd quarter 2018.

This notice comes in the wake of the recent Special Report in The New England Journal of Medicine authored by NIDA director Nora D. Volkow, and NIH director Francis S. Collins entitled "The Role of Science in Addressing the Opioid Crisis" which calls for "safer, more effective treatments" for pain. CerSci's CT-044 alleviates acute and prevents chronic pain by neutralizing excessive peroxynitrite following injury; its initial use will be to treat post-surgical pain thus providing patients, clinicians, and caregivers an alternative to opioid usage. CerSci's patented lead molecular asset, CT-044, is an orally-bioavailable, peripherally-acting, non-metal based catalytic peroxynitrite neutralizer. CT-044 has demonstrated robust efficacy across a battery of pre-clinical post-surgical pain models while exhibiting a favorable safety and toxicology profile across multiple species.

Dr. Scott L. Dax, CerSci Co-Founder and Chief Scientific Officer, is the principal investigator on the awarded SBIR, and inventor of CT-044. He has been working in the pharmaceutical industry for over 25 years, and has supervised research teams conducting pain research, advancing numerous NCEs (New Chemical Entities) into clinical development. Dr. Dax defines the CerSci mission as a calling to end human suffering by discovering and developing new therapies to conquer pain. "Speaking from my experiences spanning decades and many programs, CT-044 and the CerSci scientific platform, coupled with the synergistic expertise of our team is truly special; the opportunity and potential are something different from anything I have seen. I am grateful for this grant award because after all our hard work, CT-044 can finally enter clinical trials and soon thereafter help patients. CerSci can be the company to help patients truly in need and end this awful opioid crisis."

This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About CerSci Therapeutics
CerSci is dedicated to pharmaceutical research and development in the area of non-opioid therapeutics for the alleviation of acute and chronic pain. CerSci is currently preparing its lead drug candidate, CT-044, for Investigational New Drug (IND) application to the Food and Drug Administration (FDA), which will enable human clinical trials (expected to commence in late 2018).

Media Contact:
Lucas Rodriguez
+1 (956) 279-6888
www.CerSci.com

View original content with multimedia:http://www.prnewswire.com/news-releases/cersci-therapeutics-awarded-phase-ii-sbir-grant-from-the-national-institute-on-drug-abuse-of-the-national-institutes-of-health-300497232.html


'/>"/>
SOURCE CerSci Therapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Non-Opioid Drug Development Firm, CerSci Therapeutics, Announces Appointment of Pharma Leaders Pat Confalone and Perry Molinoff to the Board of Directors
2. CerSci Therapeutics Awarded $225K Phase I NIH SBIR Grant for the Treatment of Neuropathic Pain
3. United Therapeutics Corporation to Report Second Quarter 2017 Financial Results Before The Market Opens on Thursday, July 27, 2017
4. Prime Therapeutics Urges Caution on Mandates of Abuse-Deterrent Formulations of Opioids Citing Value Concerns
5. Breakthrough Regenerative Therapeutics Company Establishes Scientific Advisory Board
6. Prostate Cancer Therapeutics Market ; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Sales - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
7. Atara Biotherapeutics, Inc. Leases First of Nine Buildings Underway in Conejo Spectrum by SRG Commercial
8. Spero Therapeutics Highlights Potentiator Program Data at the 27th European Congress of Clinical Microbiology and Infectious Diseases
9. Abide Therapeutics Announces Dosing of First Patient In Phase 1b Study of ABX-1431 in Tourette Syndrome and Collaboration with Tourette Association of America
10. H1 Pipeline on Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) for 2017 Market Therapeutics Growth and Assessment at ReportsnReports.com
11. Dermata Therapeutics, LLC and Villani, Inc. Announce a Global License Agreement for a Natural Sponge Product for Skin Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
(Date:10/12/2017)... ... 2017 , ... Vohra Chief Medical Officer Dr. Shark Bird, ... nursing facility medical directors and other clinicians at various events in October. His ... many of these conferences we get to educate other physicians, facility nurses, corporate ...
Breaking Medicine News(10 mins):